Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

sease progression seen in the everolimus plus tamoxifen treatment arm reinforces the potential benefit of inhibiting mTOR to help overcome endocrine therapy resistance," said Thomas Bachelot, MD, from Centre Leon Berard in Lyon, France, and principal investigator of the study. "Based on these results, additional studies will evaluate the combination of everolimus with hormonal therapies as a second-line treatment for patients with HR+/HER2- metastatic breast cancer."

Breast cancer patients with advanced disease who become resistant to hormonal therapies have limited treatment options(2). Prior to these study findings, Novartis Pharmaceuticals Corporation ("Novartis") initiated a Phase III trial program called BOLERO (Breast cancer trials of OraL EveROlimus), which is the largest international Phase III clinical trial program to study an mTOR inhibitor in patients with locally advanced or metastatic breast cancer(4,5,6).

"These results are encouraging because if everolimus is approved for this indication, it could offer physicians a new strategy to treat patients with metastatic breast cancer whose disease progresses or becomes resistant to traditional hormonal therapies," said Herve Hoppenot, President, Novartis Oncology. "Novartis has a Phase III study underway researching the potential of everolimus for this patient population, which currently has limited treatment options."

For more information about the BOLERO trials, healthcare professionals can visit www.clinicaltrials.gov. Study Details This randomized Phase II trial evaluated the efficacy and safety of everolimus in 111 patients with HR+/HER2- metastatic breast cancer with prior exposure to AI treatment (in adjuvant and/or metastatic setting). Patients were randomized 1:1 to receive everolimus plus tamoxifen (10 mg/day plus 20 mg/day, respectively) [N=54] or tamoxifen alone (20 mg/day) [N=57]. The primary endpoint was clinical benefit rate, d
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... , Feb. 11 The American Academy of Pain ... Presidential Commendations and Awards presented by the Academy,s Immediate Past President, ... recipients were recognized at AAPM,s 26th Annual Meeting held in ... physicians convened to learn the latest in Pain Medicine. , ...
... , , CAMBRIDGE, Mass. , ... SHPGY ), the global specialty biopharmaceutical company, today presented positive ... and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy ... were presented in an oral presentation at the Lysosomal Disease ...
Cached Medicine Technology:The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 2The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 3The American Academy of Pain Medicine Announces this Year's Presidential Commendations and Awards 4Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 2Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 3Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 4Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 5Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 6Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease 7
(Date:5/19/2013)... York (PRWEB) May 19, 2013 ... a federal litigation now underway in U.S. District Court, ... Management Order dated May 3rd, the Court has modified ... Pool to eight cases rather than four. The next ... for Thursday, May 23rd. (In re: Actos Product Liability ...
(Date:5/19/2013)... May 19, 2013 6Webs.com is the ... companies. Homeowners who are considering an alarm system can ... the nation's leading security system providers online at 6Webs.com. ... best DIY home security system companies, 6Webs.com ... reviews dozens of home security companies before ranking the ...
(Date:5/19/2013)... May 19, 2013 Americans live closer ... the newest American Veterinary Medical Association (AVMA) U.S. Pet ... dog owners consider their dog a member of the ... said as much five years earlier. , According to ... of the national income dedicated to pets has increased ...
(Date:5/19/2013)... 2013 Yeast infections are common in both ... areas of the human body. A new yeast infection treatment ... provides a unique method of application to help eliminate over ... now provided to men and women searching for a natural ... the body through food and is stored in the intestines. ...
(Date:5/19/2013)... 19, 2013 Buenos Aires, Argentina: Yoga classes ... in Buenos Aires, Argentina by the Sivananda Yoga ... Bustamante 2372 - (Barrio Norte). Classes are 90 minutes ... classes are offered in a calm environment, allowing visitors ... and healthy vegetarian food, among others. , The Yoga ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2
... Excellence and Accountability in Kidney Care" to reduce mortality by 20 ... , WASHINGTON, June 9 Kidney Care Partners ... reduce mortality among first-year dialysis patients -- those at the greatest ... by the end of 2012. , , The ...
... SEIU UHW, of the more than 12,000 families who rely ... loved ones will hold a vigil on Tuesday at noon ... clock ticks down to the July 1st deadline for dangerous ... members fear that the lower wages will force workers to ...
... study finds , TUESDAY, June 9 (HealthDay News) -- Teens ... are less apt to become depressed or have suicidal thoughts ... shows. , "This study bolsters the argument that a lack ... an assistant professor of psychiatry at Columbia University Medical Center ...
... 9 Nationally-recognized elder care expert Doctor Marion(R) ( ... received two different accolades in one week, reinforcing her ... people caring for aging parents and loved ones. On ... College Alumni Achievement Award, presented at the college,s ...
... Legendary tennis great will appear in Cole Schotz Celebrity Match ... , NEW CITY, N.Y., June 9 Tennis legend ... 20+ year career, will appear at The Kennedy Funding Invitational, ... fight breast cancer. The fourth annual event will be held ...
... WAT-AAH!, The First Sugar-Free Functional Beverage Made Specifically for Kids, ... 9 WAT-AAH!, the first sugar-free functional beverage brand made ... results of their first nationwide WAT-AAH! Challenge to defy the ... sugar-laden drinks over water. , , During the ...
Cached Medicine News:Health News:Kidney Community Launches Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients in Iowa 2Health News:Kidney Community Launches Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients in Iowa 3Health News:Families, Consumers of Home Care Impacted by Budget Cuts to Hold Noon Vigil Outside Fresno Board of Supervisors Meeting as Clock Ticks Down to July 1st Deadline 2Health News:Early Bedtime May Help Stave Off Teen Depression 2Health News:Early Bedtime May Help Stave Off Teen Depression 3Health News:Elder Care Expert Doctor Marion Receives Accolades from Lehman College, Mature Market Resource Center in Same Week 2Health News:Andre Agassi Playing to Fight Breast Cancer - Tickets on Sale NOW! 2Health News:Let Water Be Water, LLC Announces Results of the 'WAT-AAH! Challenge' 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
Medicine Products: